Robert Talac: Is PRP Truly Autologous?
Robert Talac, Medical Director at Renaxis Regenerative Orthopedic Center, shared a post on LinkedIn:
“PRP Is Not Fully Autologous.
We should probably talk about that.
I’ve been in regenerative medicine for over 30 years.
For most of that time, PRP was widely accepted as the gold standard of autologous biologics.
I want to challenge that.
Here’s what’s actually in a standard PRP preparation:
- Citrate or EDTA anticoagulants (not from the patient)
- Bovine thrombin as an activator (not from thepatient)
- Calcium chloride to trigger clotting (not from the patient)
None of these are autologous. And it’s not a minor footnote.
EDTA and citrate disturb natural ionic homeostasis and alter cytokine profiles.
Bovine thrombin carries a documented immunogenicity risk, potentially triggering antibody responses against the patient’s own clotting factors.
This is not a fringe concern. It’s in the published data.
Platelet-Rich Fibrin (PRF), by contrast, uses no anticoagulant.
- Blood is drawn and immediately centrifuged.
- Clotting occurs through physiologic thrombin alone.
- No external activator, no foreign additive, no biochemical modification.
One caveat worth naming: many commercial PRF kits use silica or silicone-coated tubes as clot activators.
Those are foreign materials, too.
Which is why I use plain glass tubes (Bio-PRF) – the only truly additive-free option.
The result?
A dense autologous platelet-rich fibrin matrix. Nothing added. Nothing altered.
We’ve spent decades debating PRP activation protocols, platelet concentrations, and leucocyte ratios. Maybe the more important question is simpler:
If autologous therapy is the goal – is PRP actually”
Stay updated with Hemostasis Today.
-
Mar 24, 2026, 16:44Daniel Adunkwah: Reimagining Safety and Choice with Autologous Blood Transfusions
-
Mar 24, 2026, 16:42Peter Jaworski: The Shift in Plasma Center Locations Is About Demand, Not Economics
-
Mar 24, 2026, 16:41Apolipoprotein C3 as A Paradoxical Inhibitor of Platelet Aggregation and Thrombosis – JTH
-
Mar 24, 2026, 16:38Chris Centeno: Can Platelet Concentration Be Back-Calculated from Blood Draw Volume as a Surrogate?
-
Mar 24, 2026, 16:33Gaetan Duport: The Next Challenge for Patient Involvement at EMA
-
Mar 24, 2026, 16:27ABL Tyrosine Kinase Inhibitors Linked to Arterial Thrombosis – Blood Journals Portfolio
-
Mar 24, 2026, 16:21Wolfgang Miesbach: Infections as a Trigger for Stroke in Young Adults
-
Mar 24, 2026, 16:19Sue Hill: How a Biomedical Scientist’s Curiosity is Improving Patient Care
-
Mar 24, 2026, 16:16Seema Dawood: Platelet Satellitism – An EDTA-Dependent Cause of Pseudothrombocytopenia